David M Mott - Net Worth and Insider Trading

David M Mott Net Worth

The estimated net worth of David M Mott is at least $1.4 Billion dollars as of 2024-04-26. David M Mott is the Director, 10% Owner of Tesaro Inc and owns about 10,434,803 shares of Tesaro Inc (TSRO) stock worth over $782 Million. David M Mott is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $188 Million. David M Mott is also the 10% Owner of Ra Pharmaceuticals Inc and owns about 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $167 Million. Besides these, David M Mott also holds Adaptimmune Therapeutics PLC (ADAP) , Mirum Pharmaceuticals Inc (MIRM) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Regulus Therapeutics Inc (RGLS) , Epizyme Inc (EPZM) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Novavax Inc (NVAX) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , Genocea Biosciences Inc (GNCAQ) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) . Details can be seen in David M Mott's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David M Mott has not made any transactions after 2022-11-17 and currently still holds the listed stock(s).

Transaction Summary of David M Mott

To

David M Mott Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David M Mott owns 52 companies in total, including Epizyme Inc (EPZM) , Adaptimmune Therapeutics PLC (ADAP) , and Novavax Inc (NVAX) among others .

Click here to see the complete history of David M Mott’s form 4 insider trades.

Insider Ownership Summary of David M Mott

Ticker Comapny Transaction Date Type of Owner
EPZM Epizyme Inc 2021-03-26 director
ADAP Adaptimmune Therapeutics PLC 2020-07-01 director
NVAX Novavax Inc 2021-09-23 director
MRSN Mersana Therapeutics Inc 2020-04-07 director
ARDX Ardelyx Inc 2022-11-17 director
IMRA Imara Inc 2022-02-23 director
CSPR Casper Sleep Inc 2020-02-06 10 percent owner
BDTX Black Diamond Therapeutics Inc 2020-01-29 10 percent owner
RGLS Regulus Therapeutics Inc 2019-05-07 10 percent owner
SPT Sprout Social Inc 2019-12-12 10 percent owner
GRTX Galera Therapeutics Inc 2019-11-06 10 percent owner
OYST Oyster Point Pharma Inc 2019-10-30 10 percent owner
NET Cloudflare Inc 2019-09-12 10 percent owner
MIRM Mirum Pharmaceuticals Inc 2019-07-22 10 percent owner
GNCAQ Genocea Biosciences Inc 2019-06-24 10 percent owner
NITE Nightstar Therapeutics PLC 2019-06-07 director & 10 percent owner
TRVI Trevi Therapeutics Inc 2019-05-09 10 percent owner
AVEO AVEO Pharmaceuticals Inc 2019-04-08 10 percent owner
TSRO Tesaro Inc 2019-01-22 director & 10 percent owner
RARX Ra Pharmaceuticals Inc 2018-12-14 10 percent owner
MLND Millendo Therapeutics Inc 2018-12-07 10 percent owner
PHASQ PhaseBio Pharmaceuticals Inc 2018-10-17 10 percent owner
MRKR Marker Therapeutics Inc 2018-10-17 10 percent owner
ESTC Elastic NV 2018-10-04 10 percent owner
MULE MuleSoft Inc 2018-05-01 10 percent owner
SURF Surface Oncology Inc 2018-04-23 10 percent owner
TCON TRACON Pharmaceuticals Inc 2018-03-27 10 percent owner
CASC Cascadian Therapeutics Inc 2018-03-09 10 percent owner
ABIO ARCA biopharma Inc 2018-02-26 10 percent owner
APPN Appian Corp 2017-11-27 10 percent owner
SYBX Synlogic Inc 2015-09-30 10 percent owner
SBBP Strongbridge Biopharma PLC 2018-01-01 10 percent owner
XFOR X4 Pharmaceuticals Inc 2017-11-20 10 percent owner
CRCM Care.com Inc 2017-11-06 10 percent owner
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 10 percent owner
AKAOQ Achaogen Inc 2016-12-19 10 percent owner
ROKA Sorrento Tech Inc 2016-09-21 10 percent owner
ILIU Interleukin Genetics Inc 2016-07-29 10 percent owner
AVTX Avalo Therapeutics Inc 2015-10-14 10 percent owner
CSBR Champions Oncology Inc 2015-03-11 10 percent owner
BOX Box Inc 2015-01-22 10 percent owner
CVT Cvent Inc 2014-11-25 10 percent owner
DERM Dermira Inc 2014-10-08 10 percent owner
LOXO Loxo Oncology Inc 2014-08-06 10 percent owner
HIVE Aerohive Networks Inc 2014-04-02 10 percent owner
GLYC GlycoMimetics Inc 2014-01-09 10 percent owner
CLVSQ Clovis Oncology Inc 2011-11-21 10 percent owner
WDAY Workday Inc 2012-10-11 10 percent owner
MM Millennial Media Inc 2012-10-29 10 percent owner
TPST Tempest Therapeutics Inc 2018-12-07 10 percent owner
ELVN Enliven Therapeutics Inc 2020-03-11 director
GGNNQ Genocea Biosciences Inc 2018-01-19 10 percent owner

David M Mott Latest Holdings Summary

David M Mott currently owns a total of 23 stocks. Among these stocks, David M Mott owns 10,434,803 shares of Tesaro Inc (TSRO) as of March 6, 2018, with a value of $782 Million and a weighting of 54.67%. David M Mott owns 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $188 Million and a weighting of 13.14%. David M Mott also owns 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) as of October 31, 2016, with a value of $167 Million and a weighting of 11.71%. The other 20 stocks Adaptimmune Therapeutics PLC (ADAP) , Mirum Pharmaceuticals Inc (MIRM) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Regulus Therapeutics Inc (RGLS) , Epizyme Inc (EPZM) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Novavax Inc (NVAX) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , Genocea Biosciences Inc (GNCAQ) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) have a combined weighting of 20.48% among all his current holdings.

Latest Holdings of David M Mott

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TSRO Tesaro Inc 2018-03-06 10,434,803 74.96 782,192,833
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 4,909,956 38.28 187,953,116
RARX Ra Pharmaceuticals Inc 2016-10-31 3,490,073 47.99 167,488,603
ADAP Adaptimmune Therapeutics PLC 2020-01-24 102,478,668 1.08 110,164,568
MIRM Mirum Pharmaceuticals Inc 2019-07-22 4,186,243 24.46 102,395,504
AVEO AVEO Pharmaceuticals Inc 2019-04-08 2,524,387 15.00 37,865,805
MM Millennial Media Inc 2012-10-29 8,196,614 1.75 14,344,075
TRVI Trevi Therapeutics Inc 2019-05-09 4,438,562 2.78 12,339,202
ARDX Ardelyx Inc 2022-11-17 1,166,765 6.42 7,490,631
SURF Surface Oncology Inc 2018-04-23 3,312,877 1.07 3,544,778
MRSN Mersana Therapeutics Inc 2020-04-07 538,599 2.94 1,583,481
IMRA Imara Inc 2022-02-23 229,224 6.32 1,448,696
RGLS Regulus Therapeutics Inc 2019-05-07 205,245 2.42 496,693
EPZM Epizyme Inc 2021-03-26 257,859 1.47 379,053
DERM Dermira Inc 2014-10-02 17,241 18.75 323,269
ILIU Interleukin Genetics Inc 2016-07-29 55,418,811 0.00 249,385
NVAX Novavax Inc 2021-09-23 40,000 4.09 163,600
AKAOQ Achaogen Inc 2016-12-19 5,215,128 0.03 130,378
CLVSQ Clovis Oncology Inc 2011-11-21 3,419,671 0.02 51,295
TCON TRACON Pharmaceuticals Inc 2018-03-27 17,330 1.81 31,367
GNCAQ Genocea Biosciences Inc 2019-06-24 7,225,676 0.00 723
ABIO ARCA biopharma Inc 2018-02-26 0 3.58 0
APPN Appian Corp 2017-11-27 0 37.56 0

Holding Weightings of David M Mott


David M Mott Form 4 Trading Tracker

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Tesaro Inc (TSRO) over the past 5 years. The most-recent trade in Tesaro Inc is the acquisition of 145,532 shares on March 6, 2018, which cost David M Mott around $8 Million.

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 550,000 shares on October 10, 2017, which cost David M Mott around $9 Million.

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 435 shares on October 31, 2016, which brought David M Mott around $5,655.

More details on David M Mott's insider transactions can be found in the Insider Trading History of David M Mott table.

Insider Trading History of David M Mott

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David M Mott Trading Performance

GuruFocus tracks the stock performance after each of David M Mott's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David M Mott is 6.8%. GuruFocus also compares David M Mott's trading performance to market benchmark return within the same time period. The performance of stocks bought by David M Mott within 3 months outperforms 30 times out of 56 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David M Mott's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David M Mott

Average Return

9.64%

Average return per transaction

Outperforming Transactions

36%

20 out of 55 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.23 6.8 10.09 9.64 -25.07 -21.01
Relative Return to S&P 500(%) 6.27 3.75 3.17 -3.68 -37.27 -34.65

David M Mott Ownership Network

Ownership Network List of David M Mott

No Data

Ownership Network Relation of David M Mott


David M Mott Owned Company Details

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

David M Mott is the director of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Epizyme Inc Insider Transactions

No Available Data

David M Mott Mailing Address

Above is the net worth, insider trading, and ownership report for David M Mott. You might contact David M Mott via mailing address: 1119 St. Paul Street, Baltimore Md 21202.

Discussions on David M Mott

No discussions yet.